Ozempic, Eliquis, Keytruda: The 9 top-selling drugs of 2024
Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...
Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook
Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors
This was the stock's third consecutive day of losses.
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors
This was the stock's second consecutive day of losses.
Acadia Pharmaceuticals: Good Progress Means I'm Reversing My 'Sell' Call To 'Buy'
Acadia Pharmaceuticals' forecasted revenues top $1bn in 2025. Find out why ACAD stock is a "Buy" with its profitable outlook ...
What's Happening With AFRM Stock?
Following the solid Q2 beat and a guidance that met expectations, the company’s stock trended upward, surging 22% on February ...
Bristol Myers Squibb Cancer Treatment Misses Primary Endpoint in Trial
Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag, didn't meet ...
FiercePharma11h
Bristol Myers Squibb comes up short in bid to expand Opdualag in melanoma
Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...
Bristol Myers’ Phase 3 RELATIVITY-098 for Opdualag did not meet primary endpoint
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...
What's Going On With Bristol Myers Squibb Stock On Monday?
Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...